UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 10, 2006
NEW BRUNSWICK SCIENTIFIC CO., INC.
--------------------------------------------
(Exact name of registrant as specified in its charter)
NEW JERSEY 0-6994 22-1630072
-------------------- ------ ----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
P.O. BOX 4005
44 TALMADGE ROAD
EDISON,NEW JERSEY 08818-4005
------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (732) 287-1200
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF
DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On October 8, 2006, Joel Jaffe, a director of New
Brunswick Scientific Co., Inc., died following a brief illness. Mr. Jaffe also
served as Chair of New Brunswick Scientific Co., Inc.'s Audit Committee. The
Board of Directors has made no decision as to whether or not the resulting
vacancy on the Board will be filled or when a successor will be designated for
Mr. Jaffe's position as Chair of the Audit Committee.
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
New Brunswick Scientific Co., Inc.
Date: October 10, 2006 By: /s/ Thomas Bocchino
--------------------
Thomas Bocchino
Vice President, Finance and
Chief Financial Officer